**ELECTION AND REMARKS** 

In response to the requirement that a single species of PKC (e.g., alpha or beta) be elected

in the claimed invention, Applicants elect alpha. Claims 1-2, 9-44 and 56-61 read on the elected

species.

In response to the requirement that a single agent be further elected in the claimed

invention of the above-elected species, Applicants elect Group D (inhibitor of PKC). Claims 1-2,

9, 22-26, 28, 30-44, and 59-61 read on the elected species.

In response to the requirement that if D is elected, Applicants are then required to further

elect an ultimate species of "inhibitor" recited in claims 22-26 and 40-43. Accordingly,

Applicants elect the species set forth in claim 25 "wherein said inhibitor . . . changes the

phosphorylation state of protein kinase C-alpha." Claims 1, 2, 9, 25, 26, 28, 30-44, and 59-61

read on this further elected species. If the Examiner requires that a species of the inhibitor of

claim 25 be further elected, Applicants elect tocopherol. Claims 1, 2, 9, 25, 26, 28, 30-44, and

59-61 read on this further elected species.

The above-elections are made without traverse.

Applicants now believe that they have fully responded to the Restriction/Election

Requirements issued by the Office, and that the claims are in condition for examination. Early

and favorable action on the merits is respectfully requested.

-2-

Applicants: Jan MENNE *et al.* Application No. 10/528,806

No fee is believed to be required. However, if a fee is determined to be due, please charge the amount to our Deposit Account No. 22-0261. A Fee Transmittal is attached for this purpose.

Respectfully submitted,

Date: July 2, 2007

Steven R. Ludwig, Ph.D. Registration No. 36,203

VENABLE LLP

P.O. Box 34385

Washington, D.C. 20043-9998 Telephone: (202) 344-4000 Telefax : (202) 344-8300

SRL/SJB DCDocs2/873051